Sex differences of urinary and kidney globotriaosylceramide and lyso-globotriaosylceramide in fabry mice

Journal of Lipid Research

Volumn 52, Issue 9, 2011, Pages 1742-1746

  Durant, Brandon ^a   Forni, Sabrina ^a   Sweetman, Lawrence ^a   Brignol, Nastry ^b   Meng, Xing Li ^a   Benjamin, Elfrida R ^b   Schiffmann, Raphael ^a   Shen, Jin Song ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b Amicus Therapeutics Inc   (United States)

Author keywords

Glycosphingolipids; Mass spectrometry; Testosterone; Urine

Indexed keywords

ALPHA GALACTOSIDASE; CERAMIDE DERIVATIVE; GLOBOTRIAOSYLCERAMIDE; LYSOGLOBOTRIAOSYLCERAMIDE; MESSENGER RNA; TESTOSTERONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FABRY DISEASE; FEMALE; GENOTYPE; HEMIZYGOSITY; HOMOZYGOSITY; KIDNEY; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEX DIFFERENCE; TANDEM MASS SPECTROMETRY; TISSUE DISTRIBUTION; URINALYSIS; URINE LEVEL; WILD TYPE;

ALPHA-GALACTOSIDASE; ANIMALS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; FABRY DISEASE; FEMALE; HUMANS; KIDNEY; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; SEX CHARACTERISTICS; TANDEM MASS SPECTROMETRY; TRIHEXOSYLCERAMIDES;

EID: 80051817507     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M017178     Document Type: Article

References (25)

1. Schiffmann, R. 2009. Fabry disease. Pharmacol. Ther. 122: 65-77.
2. Brady, R O, A E Gal, R M Bradley, E. Martensson, A L Warshaw, and L. Laster. 1967. Enzymatic defect in Fabry disease: Ceramide trihexosidase deficiency. N. Engl. J. Med. 276: 1163-1167.
3. Shen, J S, X L Meng, D F Moore, J M Quirk, J A Shayman, R. Schiffmann, and C R Kaneski. 2008. Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol. Genet. Metab. 95: 163-168.
4. Schiffmann, R., J B Kopp, H A Austin 3rd, S. Sabnis, D F Moore, T. Weibel, J E Balow, and R O Brady. 2001. Enzyme replacement therapy in fabry disease: A randomized controlled trial. JAMA. 285: 2743-2749. (Pubitemid 32525371)
5. Eng, C M, M. Banikazemi, R E Gordon, M. Goldman, R. Phelps, L. Kim, A. Gass, J. Winston, S. Dikman, J T Fallon, et al. 2001. A phase 1/2 clinical trial of enzyme replacement in fabry disease: Pharmacokinetic, substrate clearance, and safety studies. Am. J. Hum. Genet. 68: 711-722. (Pubitemid 32202764)
6. Eng, C M, N. Guffon, W R Wilcox, D P Germain, P. Lee, S. Waldek, L. Caplan, G E Linthorst, and R J Desnick. 2001. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N. Engl. J. Med. 345: 9-16. (Pubitemid 32634266)
7. Ohshima, T., G J Murray, W D Swaim, G. Longenecker, J M Quirk, C O Cardarelli, Y. Sugimoto, I. Pastan, M M Gottesman, R O Brady, et al. 1997. alpha-Galactosidase A deficient mice: A model of Fabry disease. Proc. Natl. Acad. Sci. USA. 94: 2540-2544. (Pubitemid 27136911)
8. Ohshima, T., R. Schiffmann, G J Murray, J. Kopp, J M Quirk, S. Stahl, C C Chan, P. Zerfas, J H Tao-Cheng, J M Ward, et al. 1999. Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice. Proc. Natl. Acad. Sci. USA. 96: 6423-6427. (Pubitemid 29256681)
9. Ioannou, Y A, K M Zeidner, R E Gordon, and R J Desnick. 2001. Fabry disease: Preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice. Am. J. Hum. Genet. 68: 14-25. (Pubitemid 32048358)
10. Shiozuka, C., A. Taguchi, J. Matsuda, Y. Noguchi, T. Kunieda, K. Uchio-Yamada, H. Yoshioka, R. Hamanaka, S. Yano, S. Yokoyama, et al. 2010. Increased globotriaosylceramide levels in a transgenic mouse expressing human {alpha}1,4-galactosyltransferase and a mouse model for treating Fabry disease. J. Biochem. 149: 161-170.
11. Marshall, J., K M Ashe, D. Bangari, K. McEachern, W L Chuang, J. Pacheco, D P Copeland, R J Desnick, J A Shayman, R K Scheule, et al. 2010. Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease. PLoS ONE. 5: e15033.
12. Choi, J O, M H Lee, H Y Park, and S C Jung. 2010. Characterization of Fabry mice treated with recombinant adenoassociated virus 2/8-mediated gene transfer. J. Biomed. Sci. 17: 26.
13. Ogawa, K., Y. Hirai, M. Ishizaki, H. Takahashi, H. Hanawa, Y. Fukunaga, and T. Shimada. 2009. Long-term inhibition of glycosphingolipid accumulation in Fabry model mice by a single systemic injection of AAV1 vector in the neonatal period. Mol. Genet. Metab. 96: 91-96.
14. McCluer, R H, M A Williams, S K Gross, and M H Meisler. 1981. Testosterone effects on the induction and urinary excretion of mouse kidney glycosphingolipids associated with lysosomes. J. Biol. Chem. 256: 13112-13120. (Pubitemid 12131975)
15. McCluer, R H, C K Deutsch, and S K Gross. 1983. Testosterone-responsive mouse kidney glycosphingolipids: Developmental and inbred strain effects. Endocrinology. 113: 251-258. (Pubitemid 13045145)
16. Gross, S K, P F Daniel, J E Evans, and R H McCluer. 1991. Lipid composition of lysosomal multilamellar bodies of male mouse urine. J. Lipid Res. 32: 157-164.
17. Aerts, J M, J E Groener, S. Kuiper, W E Donker-Koopman, A. Strijland, R. Ottenhoff, C. Van Roomen, M. Mirzaian, F A Wijburg, G E Linthorst, et al. 2008. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc. Natl. Acad. Sci. USA. 105: 2812-2817. (Pubitemid 351723626)
18. Auray-Blais, C., A. Ntwari, J T Clarke, D G Warnock, J P Oliveira, S P Young, D S Millington, D G Bichet, S. Sirrs, M L West, et al. 2010. How well does urinary lyso-Gb3 function as a biomarker in Fabry disease? Clin. Chim. Acta. 411: 1906-1914.
19. Auray-Blais, C., D. Cyr, A. Ntwari, M L West, J. Cox-Brinkman, D G Bichet, D P Germain, R. Laframboise, S B Melancon, T. Stockley, et al. 2008. Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease. Mol. Genet. Metab. 93: 331-340. (Pubitemid 351192345)
20. Khanna, R., R. Soska, Y. Lun, J. Feng, M. Frascella, B. Young, N. Brignol, L. Pellegrino, S A Sitaraman, R J Desnick, et al. 2010. The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease. Mol. Ther. 18: 23-33.
21. Kusiak, J W, J M Quirk, and R O Brady. 1978. Purification and properties of the two major isozymes of alpha- galactosidase from human placenta. J. Biol. Chem. 253: 184-190.
22. Meisler, M H 1978. Synthesis and secretion of kidney beta-galactosidase in mutant le/le mice. J. Biol. Chem. 253: 3129-3134. (Pubitemid 8353187)
23. Swank, R T, K. Paigen, and R E Ganschow. 1973. Genetic control of glucuronidase induction in mice. J. Mol. Biol. 81: 225-243.
24. Takenaka, T., G J Murray, G. Qin, J M Quirk, T. Ohshima, P. Qasba, K. Clark, A B Kulkarni, R O Brady, and J A Medin. 2000. Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells. Proc. Natl. Acad. Sci. USA. 97: 7515-7520. (Pubitemid 30431495)
25. Park, J., G J Murray, A. Limaye, J M Quirk, M P Gelderman, R O Brady, and P. Qasba. 2003. Long-term correction of globotriaosylceramide storage in Fabry mice by recombinant adenoassociated virus-mediated gene transfer. Proc. Natl. Acad. Sci. USA. 100: 3450-3454. (Pubitemid 36356604)